Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

VDPHL01 is seen as a promising hair loss treatment, especially for those who can't use minoxidil due to side effects like chest pain and dizziness. Users discuss the potential benefits of combining VDPHL01 with hair transplants and express hope for fewer side effects compared to existing treatments like finasteride and dutasteride.

Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.

A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.

The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It jokingly suggests the creation of a new chemical called RU99999.

The user did not respond to minoxidil and is considering using tretinoin to improve results. They also explored finasteride, microneedling, adapalene, red light therapy, and oral minoxidil as potential treatments.

The user shared progress pictures after one year of using finasteride and minoxidil for hair loss. They initially tried microneedling but stopped due to pain and side effects.

A user discusses their experience with at-home microneedling at 1mm for hair growth, feeling like they're hitting their skull. Other users suggest lowering the needle depth or stopping due to discomfort.

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

The user is concerned that finasteride isn't improving their hair loss, as their hair has worsened over 13 months. Suggestions include adding minoxidil, considering dutasteride, and possibly a hair transplant.

Kintor edited their Amazon page, removing claims that KX-826 provides "real" visible results from clinical experiments. The discussion includes treatments like Minoxidil, finasteride, and RU58841.

A 33-year-old male is documenting his hair regrowth progress using minoxidil, red light therapy, copper peptides, and micro-needling, with noticeable improvement in hair thickness and coverage. He plans to add a topical finasteride/minoxidil spray and aims for a shadow on his scalp rather than a full head of hair.

The user is experiencing progress in hair growth using 0.5mg Finasteride, 5mg Minoxidil, and 1mg Biotin daily but is also developing gynecomastia. They plan to continue the treatment for six months unless the side effects worsen.

The user experienced significant hair regrowth using 1mg oral finasteride daily and topical minoxidil every other day, with plans to switch to oral minoxidil for consistency. They reported initial shedding and minor side effects, which resolved over time.

The conversation discusses the potential of PP405 as a hair loss treatment, with some users expressing skepticism and others hopeful about its development. There is also mention of other treatments like Minoxidil, Finasteride, and Pyrilutamide, with users debating the effectiveness and safety of self-experimentation versus waiting for clinical trial results.

The user experienced hair regrowth and strengthening using finasteride, minoxidil, micro-needling, Nizoral, and biotin products. Despite progress, they acknowledge that a hair transplant may be needed for full hairline restoration.

Two Chinese suppliers provided legitimate RU58841, confirmed through a free drug testing service. The vendors were Shaanxi Greenyo Biotech and Lyphar, found on Made-in-China.

The conversation is about using Winlevi Clascoterone cream for hair loss. The user is considering adding it to their routine, which includes a topical hair growth serum, and is seeking feedback on its effectiveness.

The user is using a regimen of topical finasteride (.025% concentration), minoxidil, Nutrafol, and vitamin D to address hair loss. They experienced initial side effects but reported improvement over 11 weeks and are considering increasing the dosage.

The user experienced significant hair improvement using 1 mg oral finasteride and 5% liquid topical minoxidil without side effects. Concerns about side effects from oral treatments were discussed, with some users sharing negative experiences with finasteride.

The user experienced significant hair regrowth using a regimen of topical Minoxidil and Finasteride, oral Finasteride, weekly microneedling, and supplements over a year. They noted improvements in the crown and temples, with minimal side effects, and plan to continue the regimen.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

The user is experiencing hair regrowth and thicker hair after two months using finasteride, biotin, a multivitamin with zinc, and Nizoral shampoo. The user expects significant improvement in hair regrowth after six months.

OP wants to increase pyrilutamide concentration from 0.5% to 1% while already using finasteride. Users suggest waiting for a commercial 1% solution and caution against using grey market products.

The user has been taking 1.25 mg of finasteride daily for over a year, noticing thicker hair and some regrowth. They plan to start using topical minoxidil, dermarolling, and mesotherapy before a hair transplant in February 2026.

A 16-year-old is experiencing hair loss and is using minoxidil, finasteride, and plans to add RU58841, while considering other treatments like MK-677 and microneedling. Concerns are raised about the potential impact of these treatments on puberty and development.

Kintor 0.9% is not effective for hair regrowth or thickening and may cause testicle sensitivity. The conversation criticizes the hype around Kintor and discusses the ineffectiveness of pyrilutamide compared to other treatments like RU58841, finasteride, and minoxidil.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

The user experienced thicker and healthier hair after 1.5 years of using finasteride daily, with no side effects. They plan to start minoxidil to enhance regrowth.

A user's 14-month journey with finasteride, microneedling, and Nizoral to treat hair loss. They experienced some side effects such as ball ache, needing to pee constantly, and less semen, but the results were generally positive.